TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin as Treatment for Alcohol Use Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-5 criteria for current alcohol use disorder~* Reports drinking a minimum of 5 standard drinks for men or 4 standard drinks for women at least 4 days per week over the past 28 days~* Between the ages of 18 and 65~* Able to provide informed consent and comply with study procedures~Exclusion Criteria:~* Subjects with any current psychiatric disorder as defined by DSM-5, other than AUD, that in the investigator's judgment might require intervention over the course of the study.~* Subjects receiving psychotropic medication treatment~* Evidence of moderate-to-severe alcohol withdrawal (CIWA-Ar \> 13)~* History of alcohol withdrawal seizures or alcohol withdrawal delirium~* History of allergic reaction to candidate medication (pregabalin)~* Pregnancy, lactation, or failure in females patients to use adequate contraceptive methods~* Unstable physical disorders which might make participation hazardous~* Subjects who have a current DSM-5 diagnosis of moderate or severe substance use disorder, with the exception of alcohol, nicotine and caffeine use disorders. A diagnosis of a mild substance use disorder will not be exclusionary, as long as the current primary substance use disorder is alcohol.~* Are legally mandated to participate in alcohol use disorder treatment program~* Cognitively impaired

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- pregabalin (Type: EXPERIMENTAL): pregabalin up to daily dose of 600 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects age ≥60 and ≤80 years at the time of signing the informed consent form.~2. Must show signs of frailty apart from a concomitant condition as assessed by the investigator with a frailty score of 1 to 4 using the Fried Phenotype Scale.~3. Must provide written informed consent.~4. Subjects are expected to live more than 12 months.~Exclusion Criteria:~1. Serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study~2. Advanced liver or renal failure, class III/IV congestive heart failure, myocardial infarction, unstable angina, cardiac revascularization, or severe obstructive ventilator defect.~3. Uncontrolled hypertension or hyperglycemia.~4. Have known allergies to biological drugs or antibiotics.~5. Expecting to receive organ transplantation.~6. Have a clinical history of malignancy or active autoimmune diseases.~7. Have a history of drug or alcohol abuse within the past 24 months.~8. Be serum-positive for HIV, hepatitis BsAg or viremic hepatitis C.~9. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.~10. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HUC-MSCs Group (Type: EXPERIMENTAL): Human umbilical cord mesenchymal stem cells (1\*10\^6/kg cells): delivered via peripheral intravenous infusion.
- Control Group (Type: PLACEBO_COMPARATOR): Placebo:normal saline delivered via peripheral intravenous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Five-Plus Year Follow-Up of SMART Randomized Controlled Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* LBP at least 6 months from original SMART Trial~* RF Ablation Arm from SMART Trial~Exclusion Criteria:~-Control Arm Subjects from SMART Trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bone and Body Comp: A Sub Study of the SECOND-LINE Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Second-Line main study identifier: NCT00931463~Inclusion Criteria:~1. HIV-1 positive by licensed diagnostic test~2. Aged 16 years or older (or minimum age as determined by local regulations or as legal requirements dictate)~3. Have received first antiretroviral regimen consisting of an NNRTI plus 2N(t)RTIs for ≥ 24 weeks~4. No change in antiretroviral therapy within 12 weeks prior to screening~5. Failed first-line NNRTI + 2N(t)RTI combination therapy according to virological criteria defined by two consecutive (≥7 days apart) HIV RNA results of \> 500 copies/mL~6. No prior or current exposure to HIV protease inhibitors and/or HIV integrase inhibitors~7. Able to provide written informed consent~Exclusion Criteria:~1. The following laboratory variables:~   * absolute neutrophil count (ANC) \< 500 cells/µL~  * hemoglobin \< 7.0 g/dL~  * platelet count \< 50,000 cells/µL~  * ALT \> 5 x ULN~2. Pregnant or nursing mothers~3. Participants with active viral hepatitis B infection defined by the presence in serum of hepatitis B surface antigen~4. Use of immunomodulators within 30 days prior to screening~5. Use of any prohibited medications (rifampicin, midazolam, triazolam, cisapride, pimozide, amiodarone, dihydroergotamine, ergotamine, ergonovine, methylergonovine, astemizole, terfenadine, vardenafil, and St. John's wort)~6. Intercurrent illness requiring hospitalisation~7. Active opportunistic disease not under adequate control in the opinion of the site Principal Investigator~8. Participants with current alcohol or illicit substance abuse that in the opinion of the site Principal Investigator might adversely affect participation in the study~9. Participants deemed by the site Principal Investigator unlikely to be able to remain in follow-up for the protocol-defined period

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1. Lopinavir / ritonavir + 2-3N(t)RTI (Type: ACTIVE_COMPARATOR): LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3N(t)RTI
- Arm 2. Lopinavir /ritonavir + raltegravir (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: China Stroke Primary Prevention Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BP≥140/90 mmHg in both of the two screening visits or currently under anti-hypertension treatment~* 45 - 75 years old~* Successful determination of MTHFR C677T genotype~* For pre-menopausal women, agreed to use contraceptives during the trial~* Signed the written informed consent~Exclusion Criteria:~* Having a history of stroke~* Having a history of myocardial infarction~* Having a history of physician diagnosed heart failure~* Post- coronary revascularization~* Severe somatic disease such as cancer~* Secondary hypertension~* Congenital or acquired organic heart diseases~* Contraindicated to angiotensin-converting enzyme inhibitor(ACEI)~* History of ACEI adverse effects~* Currently long-term use of folic acid or vitamin B12 or vitamin B6~* Pregnant or child breastfeeding women~* Severe mental disorders~* Lab tests indicating abnormal liver or kidney function~* Unwilling to participate the trial, unwilling to change the current antihypertensive treatment

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Enalapril/folic acid (Type: EXPERIMENTAL): A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
- Enalapril (Type: ACTIVE_COMPARATOR): Enalapril maleate 10 mg per day is given

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnoses of possible or probable Alzheimer's disease (NINCDS-ADRDA)~2. Presence of a caregiver (friend or relative) who can assume responsibility for medication compliance, can accompany the patient to all visits, and rate patient's condition~3. Written informed consent from both the patient (or surrogate) and caregiver~4. An MMSE score between 12 and 26 inclusive~5. Administration of a maintenance dosage of donepezil (5-10mg/d), rivastigmine (6-12mg/d) or rivastigmine (Exelon) patch (4.6 mg or 9.5 mg), galantamine or galantamine ER (16-24mg/d) for a minimum of 4 weeks prior to randomization~6. Agreement not to take vitamin E supplements and/or memantine outside of the study (daily multivitamin is permitted containing up to 100 IU alpha-tocopherol)~Exclusion Criteria:~1. A non-Alzheimer primary dementia (e.g., vascular dementia, Lewy body dementia, fronto-temporal dementia, vitamin B-12 deficiency, hypothyroidism)~2. Current major depression, delirium, alcohol or psychoactive substance abuse or dependency, schizophrenia, or delusional disorder as defined by DSM-IV~3. Presence of any uncontrolled systemic illness that would interfere with participation in the study or a life expectancy of less than one year~4. Pregnant or intention to become pregnant~5. Enrollment in another interventional clinical trial~6. Current prescription with more than one AChE inhibitor~7. Current prescription for warfarin~8. Use of vitamin E supplements in the past 2 weeks~9. Use of memantine in the past 4 weeks or known intolerance~10. Estimated creatinine clearance less than 5ml/min (Cockcroft-Gault formula)~11. Use of amantadine in the past 2 weeks

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): 2,000 IU per day of dl-alpha-tocopherol plus placebo for memantine
- Arm 2 (Type: EXPERIMENTAL): 20 mg per day of memantine plus placebo for dl-alpha-tocopherol
- Arm 3 (Type: EXPERIMENTAL): Combination of 2,000 IU per day of dl-alpha-tocopherol and 20 mg per day of memantine
- Arm 4 (Type: PLACEBO_COMPARATOR): Matching placebos for dl-alpha-tocopherol and memantine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria for patients with acromegaly:~* Male or female patients between 18 and 80 years~* Patients with acromegaly due to a pituitary adenoma with elevated GH and IGF-1 concentrations~Exclusion criteria for patients with acromegaly:~* Patients with compression of the optic chiasm causing any visual field defect~* Specific criteria apply for patients who have received certain types of therapies such as radiotherapies, surgeries, chemo- or immunotherapies in the months prior to study start~* Female patients who are pregnant or lactating~Inclusion criteria for patients with carcinoid disease:~* Male or female patients aged ≥18 years~* Patients with histologically confirmed, metastatic carcinoid tumors of the digestive system~* Patients with elevation of chromogranin-A (CgA) and/or serotonin~* Patients who are not adequately controlled by somatostatin analogues~Exclusion criteria for patients with carcinoid disease:~* Specific criteria apply for patients who have received certain types of therapies such as radiotherapies, surgeries, chemo- or immunotherapies in the months prior to study start~* Female patients who are pregnant or lactating~Other protocol-defined in- and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOM230 LAR (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Novel Closed-loop Propofol and Remifentanil System Guided by Bispectral Index Compared to a TCI Open-loop System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years~* Scheduled for noncardiac surgery elective low-risk or intermediate~* Expected surgery time greater than 1 hour~* Procedure requiring general anesthesia~* Classification of the American Society of Anesthesiologists (ASA) as I or II~Exclusion Criteria:~* Pregnant women~* Surgery scheduled urgent or emergency~* Personal history of allergy to eggs or any other part of propofol~* Personal history of abnormalities or congenital or acquired cognitive sequels: infantile cerebral palsy, Down syndrome, cerebral ischemic disease, traumatic brain injury, brain tumor, autism.~* Chronic use of benzodiazepines or antipsychotics~* A patient who does not consent to participate in the study prior to surgery or before randomization~* Need for anesthetic or analgesic blockade before surgery peripheral nerve

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Closed-Loop (Type: EXPERIMENTAL): This group includes patients with randomization process be assigned to closed loop intravenous anesthesia; the system evaluates, feeds and acts according to the patient's bispectral index, excluding the anesthesiologist. This system use a variable control of specific therapeutic effect; a target value for this variable (set point); an actuator control (infusion pump), a system (patient) and a control algorithm.
- Open-Loop (Type: ACTIVE_COMPARATOR): This group includes patients with the randomization process are assigned to open loop in which the application of anesthetics is exclusively with pharmacokinetic parameters using TCI and employs mathematical models drug. For propofol used Schneider model and Minto model for remifentanil based on effective site concentration. Changes will be made by the anesthesiologist according to his criteria, trying to keep the BIS range of 40 and 60.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mass Oral Cholera Vaccination in Zanzibar

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy residents of selected vaccination sites~* Aged 2 years and older~* non-pregnant~Exclusion Criteria:~* Age less than 2 years~* Pregnant

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): This is a single arm study. All consenting, eligible participants will receive the oral cholera vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Meets 1 of the following criteria:~  * History of breast cancer (currently without malignant disease)~ * No history of breast cancer but wishes to avoid estrogen due to a perceived increased risk of breast cancer~* Must have bothersome hot flashes (defined by their occurrence of ≥ 14 times per week and of sufficient severity to make the patient desire therapeutic intervention) for ≥ 1 month before study entry~* Has undergone treatment for cancer (patients other than breast cancer survivors are eligible)~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Creatinine clearance ≥ 30 mL/min~* No hypersensitivity to magnesium oxide~* No medical or other condition(s) that, in the opinion of the investigator/sub-investigator, may compromise the objectives of the study~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, progestational agents, or gabapentin~* More than 28 days since prior and no other concurrent investigational drugs~* Concurrent tamoxifen, raloxifene, or aromatase inhibitors allowed provided patient has been on a constant dose for \> 4 weeks AND is not expected to stop the medication during the study period

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive care (magnesium oxide) (Type: EXPERIMENTAL): Patients receive magnesium oxide by mouth daily or twice daily for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At screening patients must meet the ACR criteria for fibromyalgia (i.e. widespread pain for at least 3 months, and pain in at least 11 of 18 specific tender point sites).~* At screening and randomization, patients must have a score of \>/=40mm on the Visual Analog Scale (VAS) of the Short-Form-McGill Pain Questionnaire (SF-MPQ).~Exclusion Criteria:~* Patients with other severe pain (e.g. DPN and PHN) that may confound assessment or self-evaluation of the pain associated with fibromyalgia.~* Patients with severe hepatic impairment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects~* BMI between 18 and 30 kg/m2 and Weight ≥ 60 Kg~* Subjects must be either surgically sterilized (vasectomy), or if their partner is of childbearing potential, must use two methods of contraception, one of which must be a barrier method, from the first dose until 3 months after the last dose~* Subject is able and willing to comply with the requirements of the protocol~Exclusion Criteria:~* History of clinically significant disease~* Any illness within the 4 weeks prior to the screening examination~* Any history of alcohol and/or drug of abuse addiction and/or active / past (up to 2 years before screening) nicotine consumption~* Clinically relevant deviation from normal in the physical examination and vital signs at screening or baseline~* Clinically relevant laboratory abnormalities identified at screening or baseline~* Positive tests at screening for HIV I \& II, hepatitis B and/or hepatitis C in both parts or positive tests for Syphilis, HTLV I \& II and Nucleic Acid Test (NAT) for HIV and HBV~* Positive test for urine drugs of abuse or by anamnesis (Barbiturates, Benzodiazepines, Amphetamines, Opiates, Cocaine, Cannabinoids, Methadone, Phencyclidine, and Tricyclic Antidepressants) and/or positive alcohol blood test~* Subjects who have lost or donated in excess of 400 mL of blood within 3 months prior to Day 1 of the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
- Cohort B (Type: EXPERIMENTAL): Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
- Cohort C (Type: EXPERIMENTAL): Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete